Corcept Therapeutics (CORT) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue reached $207.6 million, up from $182.5 million year-over-year, driven by hypercortisolism growth and increased prescriptions.

• Net income declined to $19.7 million from $47.2 million in Q3 2024, mainly due to higher operating expenses.

• Strong growth in hypercortisolism business, with a 42.5% increase in tablets shipped and expanded prescriber base.

• Multiple late-stage clinical programs advancing, including two NDAs for relacorilant under FDA review for hypercortisolism (Dec 2025) and ovarian cancer (July 2026).

• Cash and investments totaled $524.2 million at quarter-end, after significant stock repurchases.

Financial highlights

• Q3 2025 product revenue was $207.6 million, up from $182.5 million in Q3 2024.

• Net income for Q3 2025 was $19.7 million, down from $47.2 million year-over-year.

• Cash and investments at September 30, 2025, totaled $524.2 million.

• $50–$50.6 million in stock repurchases executed in Q3 2025.

• Gross margin remained high, with cost of sales at 2.2% of revenue for Q3 2025.

Outlook and guidance

• 2025 revenue guidance updated to $800–$850 million.

• Anticipates FDA approval of relacorilant for hypercortisolism by December 30, 2025, and for ovarian cancer by July 2026.

• Expects continued growth in Cushing’s syndrome business and accelerating demand for relacorilant.

• R&D expenditures expected to remain flat in 2026; SG&A expenses to increase due to launch preparations.

• Company expects to fund operations and R&D activities over the next 12 months and beyond without raising additional funds.